First Analysis began coverage on shares of Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) in a report published on Wednesday. The brokerage issued an overweight rating and a $41.00 price target on the stock.
A number of other equities research analysts have also recently commented on TRHC. Chardan Capital initiated coverage on shares of Tabula Rasa Healthcare in a report on Monday, July 10th. They issued a buy rating and a $19.50 target price for the company. Stifel Nicolaus reaffirmed a buy rating and issued a $16.00 target price on shares of Tabula Rasa Healthcare in a report on Friday, July 14th. Robert W. Baird upped their target price on shares of Tabula Rasa Healthcare from $17.00 to $18.00 and gave the company an outperform rating in a report on Tuesday, August 8th. Piper Jaffray Companies reaffirmed an overweight rating and issued a $20.00 target price (up from $19.00) on shares of Tabula Rasa Healthcare in a report on Wednesday, August 9th. Finally, UBS AG upped their target price on shares of Tabula Rasa Healthcare from $18.00 to $25.00 and gave the company a buy rating in a report on Wednesday, August 30th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Tabula Rasa Healthcare presently has a consensus rating of Buy and a consensus price target of $27.50.
Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its earnings results on Monday, August 7th. The company reported $0.06 EPS for the quarter, meeting analysts’ consensus estimates of $0.06. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The business had revenue of $29.70 million during the quarter, compared to analysts’ expectations of $27.84 million. Tabula Rasa Healthcare’s revenue was up 32.6% compared to the same quarter last year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/02/tabula-rasa-healthcare-inc-trhc-coverage-initiated-by-analysts-at-first-analysis.html.
In other news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $17.21, for a total transaction of $137,680.00. Following the transaction, the chief executive officer now directly owns 918,362 shares in the company, valued at $15,805,010.02. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 24,000 shares of company stock worth $527,920. Company insiders own 45.80% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Financial Consulate Inc. acquired a new position in shares of Tabula Rasa Healthcare during the third quarter worth about $222,000. California State Teachers Retirement System increased its stake in shares of Tabula Rasa Healthcare by 60.2% during the second quarter. California State Teachers Retirement System now owns 16,500 shares of the company’s stock worth $248,000 after acquiring an additional 6,200 shares during the period. State Street Corp increased its stake in shares of Tabula Rasa Healthcare by 38.9% during the second quarter. State Street Corp now owns 69,673 shares of the company’s stock worth $1,051,000 after acquiring an additional 19,506 shares during the period. Intrinsic Edge Capital Management LLC acquired a new position in shares of Tabula Rasa Healthcare during the second quarter worth about $461,000. Finally, Hood River Capital Management LLC increased its stake in shares of Tabula Rasa Healthcare by 7.5% during the second quarter. Hood River Capital Management LLC now owns 825,225 shares of the company’s stock worth $12,420,000 after acquiring an additional 57,724 shares during the period. Institutional investors and hedge funds own 27.94% of the company’s stock.
About Tabula Rasa Healthcare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
What are top analysts saying about Tabula Rasa Healthcare Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tabula Rasa Healthcare Inc. and related companies.